The emerging practice of combining kratom, a available botanical, with opioid medication – often referred to as "Kratom Lean" – presents a complex legal ambiguity. For now, the countrywide regulated status of kratom stays in flux, varying significantly by state among localities, while codeine’s r

Research chemicals, often labeled "novel psychoactive compounds," present a significant challenge due to their changing nature. These substances are typically produced for academic exploration, but are frequently encountered in the street drug scene. The absence of extensive data on their long-te

A concerning trend is appearing among people: the concurrent consumption of legal lean syrup – often containing DXM – and kratom, a tropical plant. This extremely risky pairing presents significant medical risks. Both substances on their own carry important hazard, but their synergy can worsen